GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today its launch on Aura, Epic’s specialty diagnostics ...
Whole Genome and Exome Sequencing Market · GlobeNewswire Inc. Dublin, Jan. 23, 2026 (GLOBE NEWSWIRE) -- The "Whole Genome and Exome Sequencing Market - Global Industry Size, Share, Trends, Opportunity ...
A 10-year study shows that a multipronged approach using whole exome sequencing can improve diagnostic yield in patients with ...
Although whole-exome sequencing (WES) has its limitations, particularly with respect to secondary or incidental findings, it may still shine in routine clinical care, particularly if testing is ...
A new research paper was published in Oncotarget's Volume 15 on February 5, 2024, entitled, "Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and ...
Optimized Detection of Unknown MET Exon 14 Skipping Mutations in Routine Testing for Patients With Non–Small-Cell Lung Cancer PMD and clonal hematopoiesis are both common in patients with AML in first ...
GeneDx excels in comprehensive genome and exome testing using a vast genetic database linking 400+ diseases. The company cuts diagnostic times from years to days, enhancing patient outcomes and ...
IDT's suite of NGS innovations aim to tackle longstanding bottlenecks in library preparation, targeted enrichment, and whole genome analysis.
Genetic mutations in human DNA can prevent proteins that perform important functions in the body from being formed correctly. This can lead to serious disorders that cause disease or even disability.
Scientists at the Baylor College of Medicine and collaborating institutions used complementary approaches that integrate exome sequencing and evolutionary action machine learning to identify protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results